|
1
|
Zykova MV, Bratishko KA, Buyko EE, Azarkina LA, Ivanov VV, Mihalyov DA, Trofimova ES, Danilets MG, Ligacheva AA, Konstantinov AI, Ufandeev AA, Rabtsevich ES, Drygunova LA, Zima AP, Bashirov SR, Udut EV, Belousov MV. Coal-Derived Humic Substances: Insight into Chemical Structure Parameters and Biomedical Properties. Molecules 2024; 29:1530. [PMID: 38611808 PMCID: PMC11013056 DOI: 10.3390/molecules29071530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 03/23/2024] [Accepted: 03/26/2024] [Indexed: 04/14/2024] Open
Abstract
An investigation was carried out on humic substances (HSs) isolated from the coal of the Kansk-Achinsk basin (Krasnoyarsk Territory, Russia). The coal HSs demonstrate the main parameters of molecular structure inherent to this class of natural compounds. An assessment was performed for the chemical, microbiological, and pharmacological safety parameters, as well as the biological efficacy. The HS sample meets the safety requirements in microbiological purity, toxic metals content (lead, cadmium, mercury, arsenic), and radionuclides. The presence of 11 essential elements was determined. The absence of general, systemic toxicity, cytotoxicity, and allergenic properties was demonstrated. The coal HS sample was classified as a Class V hazard (low danger substances). High antioxidant and antiradical activities and immunotropic and cytoprotective properties were identified. The ability of the HS to inhibit hydroxyl radicals and superoxide anion radicals was revealed. Pronounced actoprotective and nootropic activities were also demonstrated in vivo. Intragastric administration of the HS sample resulted in the improvement of physical parameters in mice as assessed by the "swim exhaustion" test. Furthermore, intragastric administration in mice with cholinergic dysfunction led to a higher ability of animals with scopolamine-induced amnesia to form conditioned reflexes. These findings suggest that the studied HS sample is a safe and effective natural substance, making it suitable for use as a dietary bioactive supplement.
Collapse
Affiliation(s)
- Maria V. Zykova
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Kristina A. Bratishko
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Evgeny E. Buyko
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Lyudmila A. Azarkina
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Vladimir V. Ivanov
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Dmitrii A. Mihalyov
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Evgeniya S. Trofimova
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
- Goldberg Research Institute of Pharmacology and Regenerative Medicine, 634050 Tomsk, Russia; (M.G.D.); (A.A.L.)
| | - Marina G. Danilets
- Goldberg Research Institute of Pharmacology and Regenerative Medicine, 634050 Tomsk, Russia; (M.G.D.); (A.A.L.)
| | - Anastasia A. Ligacheva
- Goldberg Research Institute of Pharmacology and Regenerative Medicine, 634050 Tomsk, Russia; (M.G.D.); (A.A.L.)
| | - Andrey I. Konstantinov
- Department of Chemistry, Lomonosov Moscow State University, Leninskiye Gory 1-3, 119991 Moscow, Russia;
| | - Alexander A. Ufandeev
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Evgenia S. Rabtsevich
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
- Tomsk State University, 634050 Tomsk, Russia
| | - Larisa A. Drygunova
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Anastasia P. Zima
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Sergey R. Bashirov
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Elena V. Udut
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| | - Mikhail V. Belousov
- Pharmaceutical Faculty, Siberian State Medical University, 634050 Tomsk, Russia; (K.A.B.); (E.E.B.); (L.A.A.); (V.V.I.); (D.A.M.); (E.S.T.); (A.A.U.); (E.S.R.); (L.A.D.); (A.P.Z.); (S.R.B.); (E.V.U.); (M.V.B.)
| |
Collapse
|
|
2
|
Seo CS, Shin HK. Quantitative Analysis of Eight Compounds in Traditional Korean Medicine, Gongjindan Using HPLC, UPLC–MS/MS, and GC–MS/MS Systems. SEPARATIONS 2023. [DOI: 10.3390/separations10040231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2023] Open
Abstract
Gongjindan (GJD) is a traditional Korean medicine consisting of four herbal medicines and two animal-derived medicines, and is taken as a tonic in Republic of Korea. In this study, the goal was to develop and validate a simultaneous analytical method to quantify eight compounds in commercially available GJD samples using high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography with tandem mass spectrometry (UPLC–MS/MS), and gas chromatography with tandem mass spectrometry (GC–MS/MS) systems. In HPLC and UPLC–MS/MS, seven components (gallic acid, 5-(hydroxymethyl)furfural, morroniside, loganin, nodakenin, decursin, and decursinol angelate) were separated and quantified using a distilled water–acetonitrile mobile phase system on a Capcell Pak UG80 C18 column and an Acquity UPLC BEH C18 column, respectively. Muscone was quantified using GC–MS/MS. The developed assays were validated by evaluating the linearity, limit of detection, limit of quantitation, recovery, and precision. In the regression equations of all compounds, the coefficient of determination was ≥0.9917, showing good linearity. The recovery was 93.70–108.17%, and the relative standard deviation values in the precision test were all <1.50%. Using the developed analysis methods, GJD samples were determined to contain the eight target compounds in concentrations from non-detected to 10.75 mg/g. The analytical assays developed and validated in this study can be used to obtain data for the quality control of commercially available GJDs and for the further expansion of efficacy and clinical studies.
Collapse
|
|
3
|
Mostafa NM, Mostafa AM, Ashour ML, Elhady SS. Neuroprotective Effects of Black Pepper Cold-Pressed Oil on Scopolamine-Induced Oxidative Stress and Memory Impairment in Rats. Antioxidants (Basel) 2021; 10:1993. [PMID: 34943096 PMCID: PMC8698347 DOI: 10.3390/antiox10121993] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 12/05/2021] [Accepted: 12/07/2021] [Indexed: 12/16/2022] Open
Abstract
Oxidative stress is usually associated with many neurodegenerative diseases. In this study, the gas chromatography-mass spectrometry (GC-MS) analysis of cold-pressed oil (CPO) from black pepper (Piper nigrum) fruits was performed and its neuroprotective effects were evaluated for the first time. The analysis of CPO revealed the presence of the lignan sesamin (39.78%), the alkaloid piperine (33.79%), the monoterpene hydrocarbons 3-carene (9.53%) and limonene (6.23%), and the sesquiterpene β-caryophyllene (10.67%). Black pepper hydrodistilled oil (HDO) was also comparatively analyzed by GC-MS to show the impact of oil isolation by two different methodologies on their components and class of compounds identified. HDO analysis revealed 35 compounds (99.64% of the total peak areas) mainly composed of monoterpene hydrocarbons (77.28%), such as limonene (26.50%), sabinene (21.36%), and β-pinene (15.53%), and sesquiterpene hydrocarbons (20.59%) represented mainly by β-caryophyllene (19.12%). Due to the low yield obtained for HDO (0.01% v/w), only CPO was chosen for the evaluation of its neuroprotective potential. Alzheimer-type dementia was induced in rats by scopolamine intraperitoneal injection (1.5 mg/kg/day) for seven days. CPO was administered orally (100 mg/kg) for a week before scopolamine administration and then concomitantly for another week. Donepezil (1 mg/kg, orally) was used as a reference drug. CPO administration significantly improved the rat behaviors as evaluated by the Morris water maze test, evident from prolongation in time spent in the platform quadrant (262.9%, compared to scopolamine) and increasing in the crossing time by 18.18% compared to the control group. The rat behavior tested by passive avoidance, showed prolongation in the step-through latency compared to control. Moreover, CPO significantly (p < 0.05) ameliorated the activities of antioxidant enzymes such as catalase, superoxide dismutase (SOD) and reduced malondialdehyde (MDA) equivalents by 22.48%, 45.41%, and 86.61%, respectively, compared to scopolamine. Furthermore, CPO administration decreased scopolamine-induced elevated acetylcholinesterase levels in rats' hippocampi by 51.30%. These results were supported by histopathological and in silico molecular docking studies. Black pepper oil may be a potential antioxidant and neuroprotective supplement.
Collapse
Affiliation(s)
- Nada M. Mostafa
- Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo 11566, Egypt
| | - Ahmed M. Mostafa
- Department of Biochemistry, Faculty of Pharmacy, Ain-Shams University, Cairo 11566, Egypt;
| | - Mohamed L. Ashour
- Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo 11566, Egypt
- Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia
| | - Sameh S. Elhady
- Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia;
| |
Collapse
|
|
4
|
Kim H, Jeon W, Hong J, Lee J, Yeo C, Lee Y, Baek S, Ha I. Gongjin-Dan Enhances Neurite Outgrowth of Cortical Neuron by Ameliorating H 2O 2-Induced Oxidative Damage via Sirtuin1 Signaling Pathway. Nutrients 2021; 13:4290. [PMID: 34959841 PMCID: PMC8707945 DOI: 10.3390/nu13124290] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 11/23/2021] [Accepted: 11/26/2021] [Indexed: 12/11/2022] Open
Abstract
Gongjin-dan (GJD) is a multiherbal formula produced from 10 medicinal herbs and has been traditonally used as an oriental medicine to treat cardiovascular diseases, alcoholic hepatitis, mild dementia, and anemia. Additionally, increasing evidence suggests that GJD exerts neuroprotective effects by suppressing inflammation and oxidative stress-induced events to prevent neurological diseases. However, the mechanism by which GJD prevents oxidative stress-induced neuronal injury in a mature neuron remains unknown. Here, we examined the preventive effect and mechanism of GJD on primary cortical neurons exposed to hydrogen peroxide (H2O2). In the neuroprotection signaling pathway, Sirtuin1 is involved in neuroprotective action as a therapeutic target for neurological diseases. After pre-treatment with GJD at three concentrations (10, 25, and 50 µg/mL) and stimulation by H2O2 (30 µM) for 24 h, the influence of GJD on Sirtuin1 activation was assessed using immunocytochemistry, real-time PCR, western blotting, and flow cytometry. GJD effectively ameliorated H2O2-induced neuronal death against oxidative damage through Sirtuin1 activation. In addition, GJD-induced Sirtuin1 activation accelerated elongation of new axons and formation of synapses via increased expression of nerve growth factor and brain-derived neurotrophic factor, as well as regeneration-related genes. Thus, GJD shows potential for preventing neurological diseases via Sirtuin1 activation.
Collapse
Affiliation(s)
- Hyunseong Kim
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Korea; (H.K.); (W.J.); (J.H.); (J.L.); (C.Y.); (Y.L.)
| | - Wanjin Jeon
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Korea; (H.K.); (W.J.); (J.H.); (J.L.); (C.Y.); (Y.L.)
| | - Jinyoung Hong
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Korea; (H.K.); (W.J.); (J.H.); (J.L.); (C.Y.); (Y.L.)
| | - Junseon Lee
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Korea; (H.K.); (W.J.); (J.H.); (J.L.); (C.Y.); (Y.L.)
| | - Changhwan Yeo
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Korea; (H.K.); (W.J.); (J.H.); (J.L.); (C.Y.); (Y.L.)
| | - Yoonjae Lee
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Korea; (H.K.); (W.J.); (J.H.); (J.L.); (C.Y.); (Y.L.)
| | - Seungho Baek
- College of Korean Medicine, Dongguk University, 32 Dongguk-ro, Ilsandong-gu, Goyang-si 10326, Korea;
| | - Inhyuk Ha
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Korea; (H.K.); (W.J.); (J.H.); (J.L.); (C.Y.); (Y.L.)
| |
Collapse
|
|
5
|
Cheng CY, Huang HC, Kao ST, Lee YC. Angelica sinensis extract promotes neuronal survival by enhancing p38 MAPK-mediated hippocampal neurogenesis and dendritic growth in the chronic phase of transient global cerebral ischemia in rats. JOURNAL OF ETHNOPHARMACOLOGY 2021; 278:114301. [PMID: 34090910 DOI: 10.1016/j.jep.2021.114301] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 05/05/2021] [Accepted: 06/02/2021] [Indexed: 06/12/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Angelica sinensis (Oliv.) Diels (ASD), commonly known as Dang Gui, is a popular Chinese herb that has long been used to treat ischemic stroke. However, the effects of ASD in chronic cerebral ischemia and its underlying mechanisms still remain unclear. AIM OF THE STUDY This study aimed to determine the effects of the ASD extract on hippocampal neuronal survival at 28 d after transient global cerebral ischemia (GCI) and to investigate the precise mechanisms underlying the p38 mitogen-activated protein kinase (MAPK)-related signaling pathway's involvement in hippocampal neurogenesis. MATERIALS AND METHODS Rats underwent 25 min of four-vessel occlusion. The ASD extract was intragastrically administered at doses of 0.25 g/kg (ASD-0.25 g), 0.5 g/kg (ASD-0.5 g), 1 g/kg (ASD-1 g), 1 g/kg after dimethyl sulfoxide administration (D + ASD-1 g), or 1 g/kg after SB203580 (a p38 MAPK inhibitor) administration (SB + ASD-1 g) at 1, 3, 7, 10, 14, 17, 21, and 24 d after transient GCI. RESULTS ASD-0.5 g, ASD-1 g, and D + ASD-1 g treatments had the following effects: upregulation of bromodeoxyuridine (BrdU) and Ki67 expression, and BrdU/neuronal nuclei (NeuN) and Ki67/nestin co-expression in the hippocampal dentate gyrus (DG); upregulation of microtubule-associated protein 2/NeuN co-expression, and NeuN and glial fibrillary acidic protein (GFAP) expression, and downregulation of tumor necrosis factor-α/GFAP co-expression in the hippocampal CA1 region; upregulation of phospho-p38 MAPK (p-p38 MAPK), phospho-cAMP response element-binding protein (p-CREB), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor A (VEGF-A) expression in the hippocampus. SB + ASD-1 g treatment abrogated the effects of ASD-1 g on the expression of these proteins. CONCLUSIONS ASD-0.5 g and ASD-1 g treatments promotes neuronal survival by enhancing hippocampal neurogenesis. The effects of the ASD extract on astrocyte-associated hippocampal neurogenesis and dendritic growth are caused by the activation of p38 MAPK-mediated CREB/BDNF, GDNF, and VEGF-A signaling pathways in the hippocampus at 28 d after transient GCI.
Collapse
Affiliation(s)
- Chin-Yi Cheng
- School of Post-baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan; Department of Chinese Medicine, Hui-Sheng Hospital, Taichung, 42056, Taiwan.
| | - Hui-Chi Huang
- Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan.
| | - Shung-Te Kao
- School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan.
| | - Yu-Chen Lee
- Department of Chinese Medicine, China Medical University Hospital, Taichung, 42056, Taiwan; Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung, 40402, Taiwan; Graduate Institute of Acupuncture Science, China Medical University, Taichung, 40402, Taiwan.
| |
Collapse
|
|
6
|
Yamagami H, Fuji T, Wako M, Hasegawa Y. Sulfated Polysaccharide Isolated from the Nacre of Pearl Oyster Improves Scopolamine-Induced Memory Impairment. Antioxidants (Basel) 2021; 10:505. [PMID: 33804892 PMCID: PMC8063846 DOI: 10.3390/antiox10040505] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 03/12/2021] [Accepted: 03/23/2021] [Indexed: 11/16/2022] Open
Abstract
Pearl and nacre have been used in traditional medicines for treating brain dysfunctions, such as epilepsy, myopia, palpitations and convulsions. We previously showed that a pearl oyster nacre extract improves scopolamine-induced memory impairments using the Y-maze, Banes maze and object recognition tests. In this study, we aimed to isolate the memory-improving substance using ion-exchange column chromatography and reverse-phase column chromatography and elucidate the molecular mechanism underlying its memory-improving activity. The isolated substance was found to be a sulfated polysaccharide with a molecular weight of approximately 750 kDa. Monosaccharide composition analysis showed that it was rich in galactose, glucose, mannose and uronic acid. Furthermore, the mRNA expression levels of oxidative stress, inflammatory response and neuroprotective factors in the cerebral cortex were investigated. Treatment with the polysaccharide increased the expression levels of the antioxidant enzymes Cu, Zn -superoxide dismutase (SOD) and catalase and attenuated the scopolamine-mediated upregulation of the inflammatory cytokines interleukin-1 and interleukin-6. In addition, the polysaccharide suppressed the decrease in the expression levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). These findings strongly suggest that the polysaccharide in the nacre extract mediated its antiamnesic effects by preventing oxidative stress and inflammation and increasing the expression levels of BDNF and NGF.
Collapse
Affiliation(s)
| | | | | | - Yasushi Hasegawa
- College of Environmental Technology, Muroran Institute of Technology, 27-1 Mizumoto, Muroran 050-8585, Japan; (H.Y.); (T.F.); (M.W.)
| |
Collapse
|
|
7
|
Gorgani S, Jahanshahi M, Elyasi L. Taurine Prevents Passive Avoidance Memory Impairment, Accumulation of Amyloid-β Plaques, and Neuronal Loss in the Hippocampus of Scopolamine-Treated Rats. NEUROPHYSIOLOGY+ 2019. [DOI: 10.1007/s11062-019-09810-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
|
8
|
Elaeagnus glabra f. oxyphylla Attenuates Scopolamine-Induced Learning and Memory Impairments in Mice by Improving Cholinergic Transmission via Activation of CREB/NGF Signaling. Nutrients 2019; 11:nu11061205. [PMID: 31141948 PMCID: PMC6627942 DOI: 10.3390/nu11061205] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Revised: 05/22/2019] [Accepted: 05/24/2019] [Indexed: 01/11/2023] Open
Abstract
We aimed to investigate the therapeutic effects of an Elaeagnus glabra f. oxyphylla (EGFO) ethanol extract in mice with scopolamine-induced memory dysfunction. Fifty male mice were randomly divided into a normal control group, a scopolamine-treated group, a scopolamine and EGFO extract-treated group, and a scopolamine and tacrine-treated group. EGFO (50 or 100 mg/kg/day) was received for 21 days. Step-through passive avoidance and Y-maze tests were performed to examine the effects of treatment on learning and memory impairments. Acetylcholine (Ach) levels and acetylcholinesterase (AchE) activity were measured via an enzyme-linked immunosorbent assay (ELISA). Levels of choline acetyltransferase (ChAT), nerve growth factor (NGF), cAMP response element-binding protein (CREB), and apoptosis-related protein expression were determined via Western blot analysis. EGFO pretreatment significantly attenuated scopolamine-induced memory impairments, relative to findings observed in the scopolamine-treated group. Levels of cholinergic factors in the brain tissues were markedly attenuated in the scopolamine-treated group. EGFO treatment also attenuated neural apoptosis in scopolamine-treated mice by decreasing the expression of apoptosis-related proteins such as Bax, Bcl2, cleaved caspase-3, and TUNEL staining. These results suggest that EGFO improves memory and cognition in a mouse model of memory impairment by restoring cholinergic and anti-apoptotic activity, possibly via activation of CREB/NGF signaling.
Collapse
|
|
9
|
Cognitive-enhancing and ameliorative effects of acanthoside B in a scopolamine-induced amnesic mouse model through regulation of oxidative/inflammatory/cholinergic systems and activation of the TrkB/CREB/BDNF pathway. Food Chem Toxicol 2019; 129:444-457. [PMID: 31077737 DOI: 10.1016/j.fct.2019.04.062] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Revised: 04/29/2019] [Accepted: 04/30/2019] [Indexed: 11/21/2022]
Abstract
Recently, our research team reported the anti-amnesic potential of desalted-hydroethanolic extracts of Salicornia europaea L. (SE-EE). In this study, we performed bioactivity-guided isolation and identification of Acanthoside B (Aca.B), from SE-EE, as the potential bioactive candidate and examined anti-amnesic activity with its potential mechanism of action using an in vivo model. S7-L3-3 purified from SE-EE showed enhanced in vitro acetylcholinesterase (AChE) inhibitory activity. The isolated S7-L3-3 was identified and characterized as Aca.B using varied spectral analyses, i.e., Nuclear magnetic resonance (NMR), Ultraviolet-visible (UV-Vis), and Electrospray ionization-mass spectrometry (ESI-MS). In the in vitro studies, Aca.B exhibited negligible toxicity and showed a dose-dependent nitric oxide inhibitory potential in Lipopolysaccharide (LPS)-stimulated BV-2 microglial cells. In the in vivo studies, the oral administration of Aca.B to mice showed enhanced bioavailability and dose-dependent repression of the behavioral/cognitive impairment by regulating the cholinergic function, restoring the antioxidant status, attenuating the inflammatory cytokines/mediators and actively enriching neurotropic proteins in the hippocampal regions of the scopolamine-administered mice.
Collapse
|
|
10
|
Bhuvanendran S, Kumari Y, Othman I, Shaikh MF. Amelioration of Cognitive Deficit by Embelin in a Scopolamine-Induced Alzheimer's Disease-Like Condition in a Rat Model. Front Pharmacol 2018; 9:665. [PMID: 29988493 PMCID: PMC6026638 DOI: 10.3389/fphar.2018.00665] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 06/04/2018] [Indexed: 12/25/2022] Open
Abstract
Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone) is one of the active components (2.3%) found in Embelia ribes Burm fruits. As determined via in vitro AChE inhibition assay, embelin can inhibit the acetylcholinesterase enzyme. Therefore, embelin can be utilized as a therapeutic compound, after further screening has been conducted for its use in the treatment of Alzheimer's disease (AD). In this study, the nootropic and anti-amnesic effects of embelin on scopolamine-induced amnesia in rats were evaluated. Rats were treated once daily with embelin (0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg) and donepezil (1 mg/kg) intraperitoneally (i.p.) for 17 days. During the final 9 days of treatment, a daily injection of scopolamine (1 mg/kg) was administered to induce cognitive deficits. Besides that, behavioral analysis was carried out to assess the rats' learning and memory functions. Meanwhile, hippocampal tissues were extracted for gene expression, neurotransmitter, and immunocytochemistry studies. Embelin was found to significantly improve the recognition index and memory retention in the novel object recognition (NOR) and elevated plus maze (EPM) tests, respectively. Furthermore, embelin at certain doses (0.3 mg/kg, 0.6 mg/kg, and 1.2 mg/kg) significantly exhibited a memory-enhancing effect in the absence of scopolamine, besides improving the recognition index when challenged with chronic scopolamine treatment. Moreover, in the EPM test, embelin treated rats (0.6 mg/kg) showed an increase in inflection ratio in nootropic activity. However, the increase was not significant in chronic scopolamine model. In addition, embelin contributed toward the elevated expression of BDNF, CREB1, and scavengers enzymes (SOD1 and CAT) mRNA levels. Next, pretreatment of rats with embelin mitigated scopolamine-induced neurochemical and histological changes in a manner comparable to donepezil. These research findings suggest that embelin is a nootropic compound, which also possesses an anti-amnesic ability that is displayed against scopolamine-induced memory impairment in rats. Hence, embelin could be a promising compound to treat AD.
Collapse
Affiliation(s)
| | - Yatinesh Kumari
- Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia
| | | | - Mohd Farooq Shaikh
- Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia
| |
Collapse
|
|
11
|
A Herbal Medicine, Gongjindan, in Subjects with Chronic Dizziness (GOODNESS Study): Study Protocol for a Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial for Effectiveness, Safety, and Cost-Effectiveness. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2017; 2017:4363716. [PMID: 29387128 PMCID: PMC5745661 DOI: 10.1155/2017/4363716] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/16/2017] [Accepted: 10/19/2017] [Indexed: 11/18/2022]
Abstract
This study protocol aims to explore the effectiveness, safety, and cost-effectiveness of a herbal medication,Gongjindan(GJD), in patients with chronic dizziness. This will be a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, clinical trial. Seventy-eight patients diagnosed with Meniere’s disease, psychogenic dizziness, or dizziness of unknown cause will be randomized and allocated to either a GJD or a placebo group in a 1 : 1 ratio. Participants will be orally given 3.75 g GJD or placebo in pill form once a day for 56 days. The primary outcome measure will be the Dizziness Handicap Inventory score. Secondary outcome measures will be as follows: severity (mean vertigo scale and visual analogue scale) and frequency of dizziness, balance function (Berg Balance Scale), fatigue (Fatigue Severity Scale) and deficiency pattern/syndrome (qi blood yin yang-deficiency questionnaire) levels, and depression (Korean version of Beck’s Depression Inventory) and anxiety (State-Trait Anxiety Inventory) levels. To assess safety, adverse events, including laboratory test results, will be monitored. Further, the incremental cost-effectiveness ratio will be calculated based on quality-adjusted life years (from the EuroQoL five dimensions’ questionnaire) and medical expenses. Data will be statistically analyzed at a significance level of 0.05 (two-sided). This trial is registered with ClinicalTrials.govNCT03219515, in July 2017.
Collapse
|